Article
Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain.
Cancer - 1 Apr 1995
Spiekermann K, O'Brien S, Estey E
Abstract excerpt
BACKGROUND: Interleukin-2 (IL-2) has produced remissions in patients with solid tumors, predominantly malignant melanoma and renal cell carcinoma. Recently, clinical trials have assessed the therapeutic benefit of this cytokine in acute myelogenous leukemia (AML). However, little is known about the potential of IL-2 to promote the growth of leukemic cells in vivo. METHODS: A patient with acute myelocytic leukemia...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.